190 related articles for article (PubMed ID: 37020164)
21. NOT OTHERWISE SPECIFIED T-CELL LYMPHOMA: OUTCOMES OF A SINGLE CENTER STUDY.
Kriachok I; Tytorenko I; Shudrak N; Aleksik O; Stepanishyna Y; Kadnikova T; Pastushenko Y; Shokun N; Rudiyk T; Bushuieva M
Exp Oncol; 2024 Feb; 45(4):474-482. PubMed ID: 38328842
[TBL] [Abstract][Full Text] [Related]
22. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
Pfreundschuh M; Trümper L; Kloess M; Schmits R; Feller AC; Rudolph C; Reiser M; Hossfeld DK; Metzner B; Hasenclever D; Schmitz N; Glass B; Rübe C; Loeffler M;
Blood; 2004 Aug; 104(3):626-33. PubMed ID: 14982884
[TBL] [Abstract][Full Text] [Related]
23. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
24. Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma.
Liang X; Guo L; Hu X; Li S; Wen S
Medicine (Baltimore); 2021 Apr; 100(13):e25194. PubMed ID: 33787601
[TBL] [Abstract][Full Text] [Related]
25. Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas.
Jia B; Hu S; Yang J; Zhou S; Liu P; Qin Y; Gui L; Yang S; Lin H; Zhang C; Xing P; Wang L; Dong M; Zhou L; Sun Y; He X; Shi Y
Hematology; 2016 Oct; 21(9):536-41. PubMed ID: 27077778
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma.
Wang J; Su N; Fang Y; Ma S; Zhang Y; Cai J; Zou Q; Tian X; Xia Y; Liu P; Li Z; Huang H; Huang H; Cai Q
Front Immunol; 2022; 13():835103. PubMed ID: 35185926
[TBL] [Abstract][Full Text] [Related]
27. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Pfreundschuh M; Zwick C; Zeynalova S; Dührsen U; Pflüger KH; Vrieling T; Mesters R; Mergenthaler HG; Einsele H; Bentz M; Lengfelder E; Trümper L; Rübe C; Schmitz N; Loeffler M;
Ann Oncol; 2008 Mar; 19(3):545-52. PubMed ID: 18065407
[TBL] [Abstract][Full Text] [Related]
28. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.
Mercadal S; Briones J; Xicoy B; Pedro C; Escoda L; Estany C; Camós M; Colomo L; Espinosa I; Martínez S; Ribera JM; Martino R; Gutiérrez-García G; Montserrat E; López-Guillermo A;
Ann Oncol; 2008 May; 19(5):958-63. PubMed ID: 18303032
[TBL] [Abstract][Full Text] [Related]
29. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
[TBL] [Abstract][Full Text] [Related]
30. Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.
Burke JM; Liu N; Yu KS; Fanale MA; Surinach A; Flores C; Lisano J; Phillips T
Oncologist; 2023 Jun; 28(6):520-530. PubMed ID: 36971492
[TBL] [Abstract][Full Text] [Related]
31. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
Frontzek F; Ziepert M; Nickelsen M; Altmann B; Glass B; Haenel M; Truemper L; Held G; Bentz M; Borchmann P; Dreyling M; Viardot A; Kroschinsky FP; Metzner B; Staiger AM; Horn H; Ott G; Rosenwald A; Loeffler M; Lenz G; Schmitz N
Lancet Haematol; 2021 Apr; 8(4):e267-e277. PubMed ID: 33667420
[TBL] [Abstract][Full Text] [Related]
32. Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma.
Wang J; Fang Y; Ma S; Su N; Zhang Y; Huang H; Li Z; Huang H; Tian X; Cai J; Xia Y; Liu P; Cai Q
Leuk Res; 2021 Dec; 111():106705. PubMed ID: 34534908
[TBL] [Abstract][Full Text] [Related]
33. Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma.
Gang AO; Pedersen MØ; Knudsen H; Lauritzen AF; Pedersen M; Nielsen SL; Brown P; Høgdall E; Klausen TW; Nørgaard P
Leuk Lymphoma; 2015 Jul; 56(7):2039-46. PubMed ID: 25379621
[TBL] [Abstract][Full Text] [Related]
34. Acute and Persistent Remission of Aggressive Natural Killer Cell Leukemia in an Older Patient Induced by Chidamide Combined with Cyclophosphamide, Vindesine, Prednisone, and Etoposide Therapy.
Lin Q; Pei R; Lu Y
Turk J Haematol; 2023 Aug; 40(3):225-226. PubMed ID: 37464744
[No Abstract] [Full Text] [Related]
35. Efficacy of a dose-intensified CHOP (Double-CHOP) regimen for peripheral T-cell lymphomas.
Iriyama N; Takahashi H; Hatta Y; Miura K; Kobayashi Y; Kurita D; Hirabayashi Y; Hojo A; Kodaira H; Yagi M; Kiso S; Uchino Y; Nakagawa M; Kusuda M; Kobayashi S; Horikoshi A; Kura Y; Yamazaki T; Sawada U; Takeuchi J
Oncol Rep; 2013 Feb; 29(2):805-11. PubMed ID: 23166041
[TBL] [Abstract][Full Text] [Related]
36. The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review.
Ashaye AO; Burnett H; Abogunrin S; Panchmatia H; Ovcinnikova O; Dalal M
Future Oncol; 2022 Feb; 18(4):519-535. PubMed ID: 34851173
[TBL] [Abstract][Full Text] [Related]
37. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
Maeda Y; Nishimori H; Yoshida I; Hiramatsu Y; Uno M; Masaki Y; Sunami K; Masunari T; Nawa Y; Yamane H; Gomyo H; Takahashi T; Yano T; Matsuo K; Ohshima K; Nakamura S; Yoshino T; Tanimoto M
Haematologica; 2017 Dec; 102(12):2097-2103. PubMed ID: 28971899
[TBL] [Abstract][Full Text] [Related]
38. Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial.
Wang Y; Zhang M; Song W; Cai Q; Zhang L; Sun X; Zou L; Zhang H; Wang L; Xue H
Am J Hematol; 2022 May; 97(5):623-629. PubMed ID: 35170082
[TBL] [Abstract][Full Text] [Related]
39. The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.
Li L; Duan W; Zhang L; Li X; Fu X; Wang X; Wu J; Sun Z; Zhang X; Chang Y; Nan F; Yan J; Li Z; Young KH; Zhang M
Br J Haematol; 2017 Sep; 178(5):772-780. PubMed ID: 28597542
[TBL] [Abstract][Full Text] [Related]
40. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens.
Trümper L; Zwick C; Ziepert M; Hohloch K; Schmits R; Mohren M; Liersch R; Bentz M; Graeven U; Wruck U; Hoffmann M; Metzner B; Hasenclever D; Loeffler M; Pfreundschuh M;
Ann Oncol; 2008 Mar; 19(3):538-44. PubMed ID: 18212092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
